Methods for treating neuropathy by agonist anti-trk-C monoclonal antibodies
US7615383B2 · kind B2 · utility
75Cited by
6References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 16, 2006 |
| Grant date | Nov 10, 2009 |
| Priority date | — |
| Expiry date | Oct 16, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.